Linearis introduces its latest laboratory with an innovative AI biomarkers analytical platform to combat metabolic diseases
With the use of artificial intelligence (AI), Linearis Labs Inc. (Montreal, Canada) are offering a comprehensive assessment of health status by analyzing 1,400 metabolomic biomarkers using mass spectrometry. Their platform aims to empower clients to enhance preventive measures, screening processes, treatment monitoring and new drug innovation.
Linearis, a pioneering company positioned at the convergence of AI and biomarker analysis, declares the opening of its latest laboratories at a site location previously held by Medicago Inc. (Quebec City, Canada). Responding to the declaration of Medicago’s termination of their operations spanning 26 years, Linearis has obtained more than 650 scientific instruments and taken on Medicago’s most experienced, specialized personnel in mass spectrometry, quality assurance and laboratory management.
The integration of AI with high-throughput automated analysis of 1,400 metabolomic biomarkers equips Linearis to more effectively pinpoint the various factors linked to metabolic diseases such as cancer, diabetes and antimicrobial resistance. This holistic approach boosts capabilities in prevention, screening, treatment monitoring and the discovery of new drugs. Benefiting from its large capacity, Linearis’ analytical services are tailored for biobanks, researchers, clinical research organizations and biopharmaceutical companies.
President and CEO of Linearis Alexandre Le Bouthillier, explains:
“We are grateful for the support from Medicago during this transaction enabling the creation of this innovative and collaborative laboratory. The identification of disease signatures not only makes prevention accessible, but it also contributes to improving the prevention, screening, discovery of treatments, and acceleration of precision medicine.”
Developing within a health landscape illuminated by the vast potential of AI, supported by esteemed institutions and partnerships, Linearis prepares to deliver ground-breaking advancements promised for the first quarter of 2024.
You may also be interested in:
- Biomarkers for oncology: an interview with Jialu Liu
- AI-supported biomarker panel identifies early-stage cancers with >99% accuracy
- Merck KGaA agrees to €1.4bn deal with Jiangsu Hengrui for cancer alliance
Yoshua Bengio, Scientific Director and Turing Award Recipient, Mila & IVADO (Montreal, Canada), continues:
“With facilities such as the metabolomics lab launched by Linearis, we are on a trajectory to collect large quantities of individualized data that would be difficult for human minds to absorb, analyze, and track, but advances in AI are changing that, opening the door to novel understanding and mitigation of diseases that are likely to be transformative for healthcare, for example to fight cancer, diabetes or antimicrobial resistance.”
